Response letter to the editor about the editorial by oppenheimer and greenberger “baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO” (2017;119:474-5)

In our editorial "Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO1 regarding the observational study,2 we stated that "the clinician must consider the great cost associated with these agents " referring to omalizumab. A supporting reference3 didn't include indirect costs (absenteeism from school or work, psychologic harms and economic hardships of uncontrolled asthma) although we did mention them. Luskin et al point out that there are indirect benefits from omalizumab that would improve its value (benefits/costs) also known as cost effectiveness ratio.

http://ift.tt/2FvyxDX